Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04599933 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)
A Phase 3 study, sponsored by Orasis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 309
- Enrollment target
NCT04599933 is a Phase 3 study that has completed, run by Orasis Pharmaceuticals. The registered enrollment target is 309 participants.
The verdict
NCT04599933, a Phase 3 study, has completed, sponsored by Orasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 309 participants
- Enrollment target
Study Summary
This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.
Interventions
- DRUG Vehicle
- DRUG CSF-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2020-10-18 |
| Est. Completion | 2022-02-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04599933
The ClinicalTrials.gov registry entry for NCT04599933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orasis Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04599933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04599933 about?
NCT04599933 is a clinical study titled "An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)". This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.
What is the current status of trial NCT04599933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 309 participants. The study started on 2020-10-18. Estimated completion is 2022-02-19.
What interventions are being tested in trial NCT04599933?
The interventions under investigation include: Vehicle (DRUG), CSF-1 (DRUG).
Who is sponsoring clinical trial NCT04599933?
This trial is sponsored by Orasis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.